Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 11 × 11.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

Commence clinical program in PTSD. Additional pipeline: Commence Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia. Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The public hearing attracted over 100 speakers and 2000 participants. The FDA has historically been passive in its oversight of CBD products.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

The Cannigma

JULY 1, 2022

What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? Preclinical studies involve exposing cells and animals to treatments to see if there are indications that the treatment could be worth evaluating in humans. The cannabis research problem.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 24, 2019

1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products.

CBD 51

CBD Tincture Pets Chronic Pain 51

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. FDA is the government agency that ensures the safety and quality of foods, drugs, cosmetics, and other like products marketed in the United States. CBD Legal and Safety Issues An FDA report presented to the U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. DENVER, Dec.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JULY 23, 2019

It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinical trials. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Cannabis Law Report

JULY 8, 2021

“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” Chief Medical Officer, Enveric Biosciences. SOURCE Enveric Biosciences. Related Links.

Treatment 98

Treatment Clinical Trials CBD Patients 98

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2021

Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Revising a provision relating to the potency of tetrahydrocannabinol in edibles dispensed by a medical marijuana treatment center [p.1, 2, line 32]. 2, line 38]. 1, line 12]. 2, line 26]. 2, line 29].

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. This article analyses media representations of medicinal cannabis in Australian medical publications. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 28, 2021

Virpax recently reported successful results of a Charles River Laboratories single dose toxicology and pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (‘IND’) enabling trials. Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

JULY 15, 2022

Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. But bottlenecks remain to doctors prescribing the controversial treatment.

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51